3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
13
Carcinoma, Ovarian Epithelial
7
Prostatic Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Esophageal Neoplasms
1
Interventions
rucaparib
1
pembrolizumab
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Male
×
rucaparib
×
Gynecologic
×
Clear all
NCT04676334
2024-05-07
CATCH-R
pharmaand GmbH
Phase 3
Completed
34 enrolled
9 charts